For a liver fibrosis panel, what is total analytical error by population (NAFLD, viral hepatitis, alcohol-related)?

Total analytical error was not explicitly reported for liver fibrosis panels in any population (NAFLD, viral hepatitis, alcohol-related), with studies instead using sensitivity, specificity, and AUROC metrics.

Abstract

No study reported an explicit total analytical error for liver fibrosis panels. Instead, papers quantified diagnostic performance using metrics such as sensitivity, specificity, AUROC, and predictive values. In nonalcoholic fatty liver disease (NAFLD), panels based on FIB-4, NAFLD Fibrosis Score, and APRI showed:

• Sensitivity ranging from 7% to 33% in general NAFLD (with negative predictive values of 98–99% when compared to transient elastography)
• In patients with Type 2 Diabetes Mellitus, FIB-4 reached sensitivities of 81.6–95.9% and AUROC values of 0.79–0.91
• In NAFLD/NASH studies incorporating novel markers (e.g., RAB14, PLIN2), sensitivities of 88–100%, specificities of 89.6–100%, and AUROC up to 0.99 were noted

In viral hepatitis, panels including Hepascore, FIB-4, APRI, and FIBROSpect II demonstrated sensitivities between 71.8% and 82%, specificities around 65–74%, and AUROC values of 0.81–0.83. For alcohol-related liver disease, tests such as Enhanced Liver Fibrosis and FibroTest yielded AUROC figures of 0.90–0.92 with negative predictive values of 97–98%, along with false positive rates of 8–45% and false negatives below 8%.

Methods

We analyzed 40 sources from an initial pool of 996, using 8 screening criteria. Each paper was reviewed for 5 key aspects that mattered most to the research question.

Data extraction

We asked a large language model to extract each data column below from each paper.

Study Population and Setting:

• Total number of participants
• Population type (NAFLD, viral hepatitis, alcohol-related liver disease)
• Mean/median age
• Gender distribution
• Specific clinical setting (e.g., liver clinic, primary care, research study)
• Inclusion and exclusion criteria

Liver Fibrosis Assessment Method:

• Primary method of fibrosis assessment (e.g., liver biopsy, transient elastography, non-invasive scoring system)
• Specific measurement techniques (e.g., FibroScan, specific scoring algorithm)
• Cutoff values used to define fibrosis stages
• Reference standard used for validation

Total Analytical Error Measurements:

• Extract quantitative data on:
  • Analytical error rates
  • Sensitivity
  • Specificity
  • Positive predictive value
  • Negative predictive value
  • Area under the receiver operating characteristic (AUROC) curve

Variability and Measurement Precision:

• Extract information on:
  • Intra-individual variability of test measurements
  • Measurement error sources
  • Reproducibility of results
  • Factors affecting measurement precision

Study Limitations and Bias Considerations:

• Identify potential sources of bias
• Spectrum effect or spectrum bias discussions
• Limitations in study design
• Generalizability of results
• Conflicts of interest
• Funding sources

Results

Characteristics of Included Studies

Total Analytical Error by Population